Articles dans des revues avec comité de lecture (167)
56.
Anghel, S. I., Correa-Rocha, R., Correa-Rochal, R., Budinska, E., Boligan, K. F., Boliganl, K. F., Abraham, S., Colombetti, S., Fontao, L., Mariotti, A., Rimoldi, D., Ghanem, G. E., Fisher, D. E., Lévy, F., Delorenzi, M., & Piguet, V. (2012). Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF. Pigment Cell & Melanoma Research, 25(4), 482-487. doi:10.1111/j.1755-148X.2012.01018.x57.
Testori, A., Suciu, S., van Akkooi, A. A., Cook, M., Ghanem, G. E., Karra Gurunath, R., Keilholz, U., van Kempen, L., Leyvraz, S., Mihm, M., Newton-Bishop, J., Patel, P., Robert, C., Schadendorf, D., de Schaetzen, G., Spatz, A., De Vries, E., & Eggermont, A. A. (2012). EORTC Melanoma Group achievements. European journal of cancer, 10(1), 112-119. doi:10.1016/S1359-6349(12)70020-458.
Lam Hoai, X. L., André, J., Del Marmol, V., Ghanem, G. E., Sales, F., & Vereecken, P. (2012). Enquête sur l'exposition aux rayons ultraviolets parmi le personnel de quatre hôpitaux bruxellois. Annales de dermatologie et de vénéréologie, 139(2), 91-102. doi:10.1016/j.annder.2011.10.41259.
Vaes, M., Bron, D., Vugts, D., Paesmans, M., Meuleman, N., Ghanem, G. E., Guiot, T., Vanderlinden, B., Thielemans, K., Van Dongen, G., Flamen, P., & Muylle, K. (2012). Safety and Efficacy of Radioimmunotherapy with 90Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study. Journal of cancer science & therapy,(394-400).60.
Id Boufker, H., Lagneaux, L., Fayyad Kazan, H., Badran, B., Najar, M., Wiedig, M., Ghanem, G. E., Laurent, G., Body, J.-J., & Journé, F. (2011). Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts. Bone, 49(6), 1219-1231. doi:10.1016/j.bone.2011.08.01361.
Journé, F., Id Boufker, H., van Kempen, L., Galibert, M.-D., Wiedig, M., Sales, F., Theunis, A., Nonclercq, D., Frau, A., Laurent, G., Awada, A., & Ghanem, G. E. (2011). TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome. British Journal of Cancer, 105(11), 1726-1732. doi:10.1038/bjc.2011.45163.
Bouwhuis, M. G., Suciu, S., Kruit, W. H., Sales, F., Stoitchkov, K., Patel, P. I., Cocquyt, V., Thomas, J., Lienard, D., Eggermont, A., Ghanem, G. E., & European Organisation for Research and Treatment of Cancer Melanoma Group, (2011). Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952. European journal of cancer, 47(3), 361-368. doi:10.1016/j.ejca.2010.10.00564.
Herraiz, C., Journé, F., Abdel-Malek, Z., Ghanem, G. E., Jimenez-Cervantes Frigo, C., & Garcia-Borron, J. C. (2011). Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT. Molecular endocrinology, 25(1), 138-156. doi:10.1210/me.2010-021765.
Lubaki, L., Ghanem, G. E., Vereecken, P., Fouty, E., Benammar, L., Vadoud Seyedi, J., Dell'Anna, M. L., Briganti, S., Picardo, M., & Heenen, M. (2010). Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus. Archives of dermatological research, 302(2), 131-137. doi:10.1007/s00403-009-0973-366.
Id Boufker, H., Lagneaux, L., Najar, M., Piccart-Gebhart, M., Ghanem, G. E., Body, J.-J., & Journé, F. (2010). The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC cancer, 10, 298. doi:10.1186/1471-2407-10-29867.
Woff, E., Garcia, C., Tant, L., Muylle, K., Ghanem, G. E., Bourgeois, P., & Flamen, P. (2010). Imaging of tumour-induced osteomalacia using a gallium-68 labelled somatostatin analogue. BMJ case reports. doi:10.1136/bcr.02.2010.2750